Longevity Research Brief from Top Voices

Longevity Research Brief from Top Voices

Public
NeoDrop Official
NeoDrop Official

Weekly tracking of Peter Attia, David Sinclair, Bryan Johnson, Rhonda Patrick on longevity research, supplements, and protocols

Longevity Research Brief from Top Voices
Longevity Research Brief from Top Voices

Longevity Digest — June 28–July 5, 2026

This week’s strongest signal is caution at the evidence boundary: Bryan Johnson’s autoimmune gastritis disclosure became a measurement project, Peter Attia narrowed the case for metformin, David Sinclair advanced ER-100 and chemical reprogramming claims under sharper scrutiny, and Rhonda Patrick stayed mostly in practical protocol territory. The digest separates what readers can reasonably discuss or test now from investigational claims that still need stronger public evidence.

Longevity Research Brief from Top Voices
Longevity Research Brief from Top Voices

Longevity Digest — June 22–28, 2026

This week’s digest centers on a rare cross-expert convergence: Sinclair, Johnson, and Patrick all discussed the same Nature Medicine paper linking accelerated biological aging with early-onset cancer risk. It also covers Attia’s updates on endometriosis, lung cancer screening, and HDL-C; Sinclair’s fasting episode; Johnson’s Immortals RX prescription-drug pivot; and Patrick’s practical guidance on movement, sleep, diet quality, and supplements.

Longevity Research Brief from Top Voices
Longevity Research Brief from Top Voices

Longevity Digest — June 8–15, 2026

This week, epigenetic reprogramming moved from theory to human trial: Life Biosciences dosed the first participant in ER-100, the world's first epigenetic reprogramming gene therapy, targeting damaged retinal cells in glaucoma patients. Sinclair relaunched his Lifespan podcast to explain the science behind it. Rhonda Patrick published a landmark 2h39min episode with Steve Horvath, who ranked interventions by how reliably they move mortality-predicting clocks — GrimAge leads, semaglutide-driven weight loss registers strongly, and partial reprogramming is promising but bounded. Peter Attia reframed brain lipidology with Tom Dayspring (statins do not harm the brain's cholesterol system) and documented a critical gap in breast cancer screening uptake. Bryan Johnson highlighted a pancreatic cancer drug that nearly doubled survival.

Longevity Research Brief from Top Voices
Longevity Research Brief from Top Voices

Longevity Digest — June 1–8, 2026

This week's digest covers a convergence moment in longevity science. Peter Attia published a deep-dive on VERVE-102's Phase I NEJM data — a single-dose gene therapy that permanently silences PCSK9 in the liver and reduced LDL-C by up to 62% durably. David Sinclair co-authored the first comprehensive epigenetic clock evidence map (41 human studies), finding rapamycin has no detectable effect on next-generation clocks while exercise, semaglutide, and calorie restriction do — alongside reacting to NewLimit's $435M raise at $3.1B. Bryan Johnson documented jet lag's physiological toll across grip strength, cortisol, and blood glucose timelines, plus a jet lag recovery protocol whose claimed "44% faster recovery" figure could not be found in the cited paper. Rhonda Patrick surfaced four well-cited studies: omega-3s reduce aggression 28% across 29 RCTs, black coffee's mortality benefit disappears with cream/sugar, and 90–120 minutes/week of strength training reduces mortality with no benefit beyond that dose. Cross-expert convergence covers PCSK9 (Attia + Johnson), exercise mortality (Sinclair + Patrick), and the compound-interest framework for biological intervention (Sinclair + Attia).

Longevity Research Brief from Top Voices
Longevity Research Brief from Top Voices

Longevity Digest — May 25–June 1, 2026

This week's digest covers four tracked experts across seven days. David Sinclair's ER-100 partial reprogramming trial (NCT07290244) entered active recruiting — the first such therapy in human subjects — while Sinclair publicly corrected a "Can Beat Death" headline back to "can beat diseases." Rhonda Patrick posted the week's highest-signal output: a 500,000-person Nature study revising the sleep sweet spot to 6.4–7.8 hours, a creatine-caffeine interaction threshold (≈350 mg pre-workout), a methodological defense of omega-3 supplementation against a flawed 2026 study, and prenatal vitamin D data showing better child memory at age 10 with 2,800 vs. 400 IU/day. Peter Attia released a three-element supplement evaluation framework and a meta-analysis-backed resistance training protocol (2×/week, moderate load, 3–4 sets) that captures 77% of optimized strength gains. Bryan Johnson's loudest post defended his UV umbrella with a claimed 9-year skin age reversal (unverified), and he highlighted VERVE-102 PCSK9 base editing (62% LDL reduction from a single infusion) as the next wave after GLP-1s.

Longevity Research Brief from Top Voices
Longevity Research Brief from Top Voices

Longevity Digest — May 17–25, 2026

This 8-day digest covers the week's most actionable output from all four tracked experts. David Sinclair's Life Biosciences closed a $120M Series D while its first-ever human epigenetic reprogramming trial (ER-100, Phase 1) ran in patients with glaucoma and NAION. Bryan Johnson formally expanded Blueprint to a female protocol (Kate Tolo), put social-media avoidance in official protocol copy, and shared a 500,000-person multi-omics study pinning optimal sleep at 6.4–7.8 hours. Rhonda Patrick surfaced a BJSM UK Biobank study (n=17,088) showing >150 min/week exercise correlates with only 8–9% CVD risk reduction vs. >30% at 560–610 min/week, and disclosed her daily phytosomal curcumin protocol. Peter Attia published a framework for when genetic testing changes clinical decisions and covered self-collection HPV testing as an adherence tool.

No more Posts
View full content archive